Dianthus Therapeutics, Inc. (DNTH) is listed on NASDAQ in Pharmaceutical Stocks. It is $105.79, -5.16%, with a $5.9B market cap. RSI is 46.8, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 46.8 Neutral
Market Cap $5.9B
Volume 418.5K
Fundamentals — 10-Q Q2 2026
Revenue --
Net Income $-91.0M
EPS $-1.75
P/E Ratio -60.5x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Read Simon | Insider | Sell | 2,778 | $117.55 | $326,554 | 2026 Aug 19 |
| McGeorge Anne | Insider | Sell | 7,750 | $109.01 | $844,822 | 2026 Aug 10 |
| Read Simon | Insider | Sell | 2,777 | $109.55 | $304,232 | 2026 Aug 10 |
| Veness Adam M | SVP, General Counsel and Sec. | Sell | 20,000 | $110.44 | $2.2M | 2026 Aug 10 |
| Garcia Marino | CEO AND PRESIDENT | Sell | 166,000 | $108.11 | $17.9M | 2026 Aug 7 |
| Savitz Ryan | EVP, CFO & CBO | Sell | 31,249 | $101.03 | $3.2M | 2026 Jul 9 |
| Veness Adam M | SVP, General Counsel and Sec. | Sell | 30,000 | $80.80 | $2.4M | 2026 Jun 17 |
| Randhawa Simrat | EVP, Head of R&D | Sell | 26,530 | $90.62 | $2.4M | 2026 Jun 1 |
| Soteropoulos Paula | Insider | Sell | 599 | $85.47 | $51,197 | 2026 May 8 |
| Savitz Ryan | EVP, CFO & CBO | Sell | 8,224 | $89.84 | $738,844 | 2026 Apr 9 |
| Savitz Ryan | EVP, CFO & CBO | Sell | 114,367 | $83.00 | $9.5M | 2026 Mar 31 |
| Soteropoulos Paula | Insider | Sell | 599 | $80.11 | $47,986 | 2026 Mar 31 |
| Soteropoulos Paula | Insider | Sell | 27,594 | $78.05 | $2.2M | 2026 Mar 24 |
| Garcia Marino | CEO AND PRESIDENT | Sell | 122,918 | $81.49 | $10.0M | 2026 Mar 12 |
| Carr Edward | CHIEF ACCOUNTING OFFICER | Sell | 43,682 | $81.49 | $3.6M | 2026 Mar 12 |
| Randhawa Simrat | EVP, Head of R&D | Sell | 33,830 | $81.48 | $2.8M | 2026 Mar 12 |
| Savitz Ryan | CFO & CBO | Sell | 20,000 | $45.18 | $903,600 | 2025 Dec 4 |
| Randhawa Simrat | EVP, Head of R&D | Sell | 196,538 | $37.55 | $7.4M | 2025 Nov 14 |
| Savitz Ryan | CFO & CBO | Sell | 20,000 | $35.00 | $700,000 | 2025 Sep 9 |
| Fairmount Funds Management LLC | Director | Buy | 24,670 | $13.63 | $336,252 | 2023 Sep 29 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $33.21 | 63.0 | -- |
| | $53.91 | 53.0 | $8.3B |
| | $65.68 | 62.9 | $6.2B |
| | $13.71 | 51.0 | $10.9B |
| | $40.94 | 41.9 | $5.5B |
Take DNTH further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put DNTH in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Dianthus Therapeutics, Inc. next reports.
Set alerts on DNTH
Get notified when Dianthus Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free